Studies people with REM sleep behavior disorder to prepare future brain-protection trials
Enrolls people with REM sleep behavior disorder and healthy volunteers, to prepare future trials.
Key facts
- Who runs it
- Washington University School of Medicine
- Where
- Atlanta, Boston, Los Angeles, Minneapolis, Portland, Redwood City, Rochester, and St Louis, United StatesSee the 8 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- North American Prodromal Synucleinopathy Consortium Stage 2
- Status
- Enrolling by invitation
- People taking part
- 500 people, planned
- Started
- 12 Aug 2022
- Expected to end
- 1 May 2028
- Type of study
- Observational, 2 groups
- Record updated
- 13 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with REM sleep behavior disorder (RBD) confirmed by a sleep study, and healthy adults as a control group.
- Age
- Adults over 18 years.
- Sex
- All sexes can join.
- Disease stage
- RBD group: REM sleep behavior disorder confirmed by an overnight sleep study (polysomnogram). Control group: no sign of RBD.
Main reasons for not taking part
- RBD group: Parkinson's disease, any dementia, or multiple system atrophy (MSA), unless the person took part in NAPS1
- RBD group: narcolepsy-related RBD, or RBD with a known cause other than an early synucleinopathy
- Control group: history of acting out dreams, parkinsonism, MSA, dementia or mild cognitive impairment
- Control group: cannot have a full MRI or a lumbar puncture
- Both groups: taking part in another clinical trial, unless the study's Executive Committee gives permission
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Polysomnogram-confirmed RBD by ICSD-3 criteria
- Capable of providing informed consent at time of study enrollment
- Age > 18 years
- Ability to provide written consent
- Age > 18 years
- Must meet age, sex, and race matching criteria per the Data Management and Statistical core recommendations for the site
- Must be willing to undergo all testing procedures, including neuroimaging and lumbar puncture
- Normal capacity to perform complex activities of daily living independently based on informant or physician report
Who cannot take part
- Diagnosis of PD, dementia of any type, or MSA unless previous participant in NAPS1
- In the opinion of the investigator, the individual has a clinically significant uncontrolled medical condition that would impede safe completion of the study protocol
- History of dream enactment behavior to suggest RBD
- Parkinsonism, MSA, dementia, or mild cognitive impairment
- Active central nervous system, systemic, psychiatric condition or use of psychoactive medication that would adversely affect cognitive, neuropsychiatric, motor, or autonomic functioning
- In the opinion of the investigator, the individual has a clinically significant uncontrolled medical condition that would impede safe completion of the study protocol
- Narcolepsy-associated RBD
- RBD secondary to any known cause except prodromal synucleinopathy
- Participation in a clinical trial, except by specific permission by the Executive Committee
- Contraindications to complete MRI
- Contraindications to lumbar puncture
- Participation in a clinical trial, except by specific permission by the Executive Committee
Where in United States
Also in 1 other country, 1 site
- Emory UniversityAtlanta, United StatesEnrolling by invitation
- Massachusetts General HospitalBoston, United StatesEnrolling by invitation
- University of California, Los AngelesLos Angeles, United StatesEnrolling by invitation
- University of MinnesotaMinneapolis, United StatesEnrolling by invitation
- Oregon Health Sciences UniversityPortland, United StatesEnrolling by invitation
- Stanford UniversityRedwood City, United StatesEnrolling by invitation
- Mayo Clinic - RochesterRochester, United StatesEnrolling by invitation
- Washington University School of MedicineSt Louis, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
The 2 groups in the trial
- RBD group
Clinical observation involving annual visits to a study site for up to 5 years.
- control group
Clinical observation involving annual visits to a study site for up to 5 years.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- North American Prodromal Synucleinopathy Consortium Stage 2
- Plain-language title
- Studies people with REM sleep behavior disorder to prepare future brain-protection trialsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- The Prodromal Synucleinopathy Rating Scale: An Assessment in Patients With REM Sleep Behavior Disorder.Neurology, 2026
- The North American Prodromal Synucleinopathy study: protocol for a multi-site, longitudinal, observational study of idiopathic/isolated rapid eye movement sleep behavior disorder.Sleep advances : a journal of the Sleep Research Society, 2026
- Record updated
- 13 May 2026